Frontlight ResearchEarly access
CompletedPhase 1/2
Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
Key facts
- Who runs it
- University of Minnesota
- Where
- Englewood and Minneapolis, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 24 people enrolled
- Started
- 1 Feb 2021
- Ended
- 1 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Brivaracetam
- Placebo
- Record updated
- 14 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Spinal cord injury (SCI)
- Participants must have completed inpatient rehabilitation and are living in the community
- Participant who have severe below-level neuropathic pain (daily average 9/10 or 10/10)
- Participants must have tried and failed to achieve adequate pain relief with the use of other drugs (i.e treatment failed to decrease their pain below a level of 9) and can continue to take spasmolytics, pregabalin, gabapentin, and opioids in unchanged dosing throughout the trial
Who cannot take part
- Epilepsy
- Contraindications to brivaracetam or pyrrolidine derivatives including allergy, or contraindications to MRI including retained bullet fragments, noncompatible metal implants, and implanted devices such as baclofen pumps
- Pprogressive myelopathy secondary to posttraumatic cord tethering
- Syringomyelia
- Brain injury limiting the ability to follow directions
- Pregnancy or lactation
- Impaired liver or renal function
Where in United States
- Swedish HospitalEnglewood, United States
- University of Minnesota School of MedicineMinneapolis, United States
About the trial
What the trial wants to find out
Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to all pharmacological intervention. Preliminary data suggest brivarecetum is a mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized, placebo-controlled pilot clinical trial will assess feasibility of a 3-month treatment course with brivarecetum.
The 2 groups in the trial
- Brivaracetam GroupTreatment being tested
Participants in this arm will receive the investigational drug, Brivaracetam.
Treatment: Brivaracetam
- Control GroupPlacebo, for comparison
Participants in this arm will receive a placebo.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Pilot Clinical Trial
- Record updated
- 14 October 2025